Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim Dealt New Blow In Nearly Two Years Of Review For Pradaxa In Australia

This article was originally published in PharmAsia News

Executive Summary

Australia’s Health Ministry calls for additional study of anticoagulant Pradaxa, dealing a fresh blow to Boehringer Ingelheim’s hopes of getting listed on the national reimbursement program nearly two years after initial regulatory approval.

You may also be interested in...



Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue

Data from the pilot program a “driving factor” in the agency’s decision against changing its recommendations for the blood thinner following reports of increased serious bleeding events.

Boehringer Ingelheim's Open Letter For Pradaxa Brings Australian PBS Back Into Spotlight

Pharmaceutical giant Boehringer Ingelheim took on the Australian federal government Nov. 2, calling for the approval of Boehringer's new anti-coagulant drug Pradaxa (dabigatran) for the country's Pharmaceutical Benefits Scheme

Battle Over Deferred Drug Listings In Australia: Should Cost-Effective Drugs Always Be Funded?

A storm is brewing in the lead up to Australia's May 10 federal budget over the nation's Pharmaceutical Benefits Scheme, which acts as a single payer to subsidize drug prices and is administered by the government

Topics

Related Companies

UsernamePublicRestriction

Register

SC080108

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel